Isoniazid is a first-line medicine for tuberculosis (TB) treatment. It is a prodrug activated by the mycobacterial catalase-peroxidase enzyme KatG. However, the development of isoniazid resistance ...

The global catalase industry is worth USD 387.4 Mn as of now and expected to reach USD 516.6 Mn by the year 2032 at a CAGR of ...

Drugmaker HLB will acquire a controlling stake in Genofocus, Korea’s top domestic enzyme producer, as part of the ...